Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Norepinephrine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NuLiv's Verbasnol Reduces Acne And Improves Skin Quality in Study
Details : Norepinephrine is an adrenergic receptor agonist, small molecule drug candidate. Diluted with sodium chloride solution the treatment of severe, acute hypotension.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : Norepinephrine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AstraGin
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NuLiv Science demonstrate the potential of AstraGin® to support overall gut health and well-being, positioning it as a promising solution for individuals with UC and other gut-related challenges.
Product Name : AstraGin
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2023
Lead Product(s) : AstraGin
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable